Loading...
•
Dec 31, 2022
Personalis Q4 2022 Earnings Report
Personalis' financial results for Q4 2022 were reported, highlighting a focus on MRD, personalized cancer vaccines, and clinical trial support.
Key Takeaways
Personalis reported Q4 2022 revenue of $16.7 million and a net loss of $31.1 million. The company is focusing on MRD, personalized cancer vaccines, and supporting pharmaceutical clinical trials.
Total company revenue for the fourth quarter of 2022 was $16.7 million.
Revenue from pharma tests, enterprise, and other customers was $15.8 million in the fourth quarter of 2022.
Revenue from population sequencing for the U.S. Department of Veterans Affairs Million Veterans Program was $0.9 million in the fourth quarter of 2022.
Net loss for the fourth quarter of 2022 was $31.1 million, or $0.67 per share.
Revenue by Segment
Forward Guidance
Personalis provided revenue and net loss guidance for Q1 2023 and full year 2023.
Positive Outlook
- Total company revenue of approximately $17.5 million for Q1 2023.
- Revenue from pharma tests, enterprise sales, and other customers of approximately $14.5 million for Q1 2023.
- Revenue from population sequencing of approximately $3.0 million for Q1 2023.
- Total company revenue in the range of $68 million to $72 million for FY 2023.
- Net loss of approximately $103 million for FY 2023, down from $113 million in 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...